Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy
- PMID: 3202908
- DOI: 10.1016/0006-2952(88)90349-8
Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy
Abstract
The activity of dihydropyrimidine dehydrogenase (DPD), the initial, rate-limiting enzyme in pyrimidine catabolism, was measured at various times over a 24-hr period in the livers of rats housed under standardized conditions of light and dark. Under "normal" conditions, i.e. lights on from 6:00 a.m. to 6:00 p.m. and off from 6:00 p.m. to 6:00 a.m., a circadian rhythm of DPD activity was observed (P less than 0.0001, Cosinor analysis) with the peak of activity at 4:00 p.m. (2.96 nmol catabolites/min/mg) and the trough at 4:00 a.m. (0.40 nmol catabolites/min/mg). Maximum enzyme activity exceeded minimum activity by more than 7-fold. Reversing the light-dark cycle (i.e. lights on from 6:00 p.m. to 6:00 a.m. and off from 6:00 a.m. to 6:00 p.m.) resulted in a corresponding shift in enzyme activity. Under these "reverse" conditions, a circadian rhythm was observed (P less than 0.0001, Cosinor analysis) with the peak of activity at 6:00 a.m. (2.87 nmol catabolites/min/mg) and the trough at 6:00 p.m. (0.92 nmol catabolites/min/mg). These studies demonstrated that DPD activity in rat liver varies over a 24-hr period in association with the light-dark cycle.
Similar articles
-
Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver.Cancer Res. 1989 Dec 1;49(23):6610-4. Cancer Res. 1989. PMID: 2819711
-
Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy.Cancer Res. 1993 Jun 15;53(12):2816-22. Cancer Res. 1993. PMID: 8504424
-
Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines.Biochem Pharmacol. 1993 Feb 9;45(3):667-73. doi: 10.1016/0006-2952(93)90141-i. Biochem Pharmacol. 1993. PMID: 8442766
-
Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.Pharmacogenomics. 2002 Jul;3(4):485-92. doi: 10.1517/14622416.3.4.485. Pharmacogenomics. 2002. PMID: 12164772 Review.
-
Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review).Anticancer Res. 1994 Nov-Dec;14(6A):2295-7. Anticancer Res. 1994. PMID: 7825962 Review.
Cited by
-
Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats.Eur J Drug Metab Pharmacokinet. 2013 Sep;38(3):171-81. doi: 10.1007/s13318-012-0114-9. Epub 2012 Nov 30. Eur J Drug Metab Pharmacokinet. 2013. PMID: 23197286
-
Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase.Br J Clin Pharmacol. 1998 Jul;46(1):1-4. doi: 10.1046/j.1365-2125.1998.00050.x. Br J Clin Pharmacol. 1998. PMID: 9690942 Free PMC article.
-
CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver.Jpn J Cancer Res. 2001 May;92(5):554-61. doi: 10.1111/j.1349-7006.2001.tb01129.x. Jpn J Cancer Res. 2001. PMID: 11376565 Free PMC article.
-
Chronopharmacokinetics of ciclosporin and tacrolimus.Clin Pharmacokinet. 2006;45(8):775-88. doi: 10.2165/00003088-200645080-00002. Clin Pharmacokinet. 2006. PMID: 16884317 Review.
-
Clinical pharmacology of 5-fluorouracil.Clin Pharmacokinet. 1989 Apr;16(4):215-37. doi: 10.2165/00003088-198916040-00002. Clin Pharmacokinet. 1989. PMID: 2656050 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases